Time filter

Source Type

Jia Y.-H.,Clinical Laboratory of Tianjin Third Central Hospital | Fan Z.-J.,Clinical Laboratory of Tianjin Third Central Hospital | Guo H.,Institute for Hepatobiliary Disease | Zhou S.-F.,Clinical Laboratory of Tianjin Third Central Hospital | Liu S.-Y.,Clinical Laboratory of Tianjin Third Central Hospital
World Chinese Journal of Digestology | Year: 2015

AIM: To investigate the correlations between hepatitis C virus (HCV) RNA load and the titers of anti-HCV antibody and anti-nuclear antibody (ANA), and the change in ANA titers before and after interferon treatment, to provide guidance for the treatment of chronic hepatitis C (CHC). METHODS: Serum samples were collected from 112 patients with CHC from January 2013 to February 2014 at Tianjin Third Central Hospital. Real-time fluorescence quantitative polymerase chain reaction (FQ-PCR) was performed to detect HCV RNA, ELISA was used for the detection of anti-HCV antibody, and indirect immunofluorescence (IIF) was performed for the detection of ANA. Spearman correlation analysis was used to analyse the correlations between Log HCV RNA and the titers of anti-HCV antibody and ANA. Independent samples t-test and K independent samples test analysis were used to analyse the correlation between Log HCV RNA and the titer of ANA. Rank sum test was used to compare ANA titers before and after treatment with interferon for one month. RESULTS: There was no correlation between HCV RNA load and the titer of anti-HCV antibody (r = 0.078, P = 0.465). There was a correlation between HCV RNA load and ANA titer (r = 0.744, P = 0.001). There was a significant difference in HCV RNA between the ANA(+)/(-) groups (P = 0.001). HCV RNA varied among different titers of ANA (χ2 = 32.58, P = 0.001). The change in ANA titers before and after interferon treatment was statistically significant (Z = 2.60, P = 0.001). Most CHC patients had a low titer of ANA. With the increase in viral load, the number of patients with a high titer of ANA had an increasing trend. CONCLUSION: HCV RNA can be used to evaluate the antiviral effect. There is a certain degree of autoimmune phenomenon in patients with CHC. Interferon can enhance autoimmunity in the course of therapy. © 2015 Baishideng Publishing Group Inc. All rights reserved. Source

Shan S.-G.,Tianjin Medical University | Gao Y.-T.,Institute for Hepatobiliary Disease | Gao Y.-T.,HIGH-TECH | Xu Y.-J.,Tianjin Medical University | And 8 more authors.
Hepatology Research | Year: 2013

Aim: Serum Golgi protein 73 (sGP73) is a novel biomarker for hepatocellular carcinoma (HCC). However, there are few reports on the pattern of GP73 expression in the progression of benign liver diseases to precancerous lesions and HCC. This study aimed to investigate GP73 expression and its correlation with clinicopathological parameters. Methods: Tissue GP73 (tGP73) levels were detected in specimens of group A (n=186) including HCC, peritumoral tissue (PTL), high/low-grade hepatic atypical hyperplasia (AH), chronic hepatitis B (CHB) and normal controls (NC) by immunohistochemistry, and GP73 expression in group B (n=159) and group C (n=16) were detected by reverse transcription polymerase chain reaction and western blot, respectively. sGP73 levels were detected in subjects of group D (n=287) by enzyme-linked immunoassay. Results: GP73 expression increased gradually from NC, CHB, PTL to high-grade AH and HCC at both protein and mRNA levels (P<0.05), while sGP73 in the HCC group was lower than in the liver cirrhosis (LC) group (P<0.001). Both tGP73 and sGP73 levels were negatively associated with tumor size and tumor-node-metastasis stage, and tGP73 levels were positively associated with tumor differentiation. The high-tGP73 group showed significantly better overall and disease-free survival than the low-tGP73 group (P=0.008, P=0.018). Multivariate analysis revealed that the tGP73 level was an independent prognostic factor for HCC, but not sGP73. Conclusion: GP73 expression pattern suggests that the regulatory mechanism of GP73 is related to the progression of chronic liver diseases. Furthermore, a high level of tGP73 is a favorable prognostic factor for HCC. © 2013 The Japan Society of Hepatology. Source

Li J.,Tianjin Medical University | Shi W.,Institute for Hepatobiliary Disease | Gao Y.,Institute for Hepatobiliary Disease | Gao Y.,HIGH-TECH | And 5 more authors.
Clinical Laboratory | Year: 2013

Background: Increasing evidence has shown that the deregulation of microRNAs (miRNAs) is closely related to the development and progression of hepatocellular carcinoma (HCC). To screen for HCC-specific miRNAs, this study investigated the differentially expressed miRNAs between HCC and matched non-tumorous tissue (NT). Methods: This study analyzed the differential expression profiles of miRNAs in 11 pairs of HCC and matched NT from 11 hepatitis B virus (HBV) infection patients with the RT2 miRNA PCR array containing 88 human cancer-related miRNAs. The fold change value was more than two between the HCC and the matched NT, which indicated that there was deregulation of miRNAs. The down-regulated let-7a was validated in another sample set of 34 tissues with the TaqMan RT-qPCR method. Results: Compared with the matched NT tissues, 9 miRNAs were up-regulated in the HCC tissues, and three were considered statistically significant (p < 0.05): miR-96, miR-183, and miR-196a, which were up-regulated 4.746-, 7.127-, and 3.498-fold, respectively. Simultaneously, 9 miRNAs were down-regulated in the HCC tissues, and two were considered statistically significant: let-7c and miR-138, which were down-regulated 3.945- and 4.790-fold, respectively. The expression levels of let-7a were 1.071 ± 0.401, 0.926 ± 0.477, 0.881 ± 1.214, and 0.535 ± 0.719 in the healthy group, chronic hepatitis B(CHB) group, NT group, and HCC group, respectively (p > 0.05). Conclusions: This study demonstrates that 18 miRNAs were deregulated in the HCC and matched NT tissues. The deregulated miRNAs suggest that further analyses with larger miRNA samples as a diagnostic marker are warranted. Source

Liu J.,Tianjin Medical University | Gao Y.,Institute for Hepatobiliary Disease | Yang B.,Institute for Hepatobiliary Disease | Jia X.,Tianjin Medical University | And 7 more authors.
Archives of Medical Research | Year: 2015

Background and Aims: Previous studies indicated Squamous Cell Carcinoma Antigen 1 (SCCA1) may be involved in tumorigenesis and progress of various human malignancies by inhibiting cell apoptosis and promoting cell proliferative activity. The aim of the study was to further investigate SCCA1 expression in different extent of liver diseases and evaluate the clinical significance and prognostic value in HCC. Methods: Eighty nine patient-matched tumors and peritumoral surgical specimens and 56 liver biopsies specimens from 23 patients with chronic hepatitis B (CHB), 19 with dysplastic nodule (DN), and 14 with HCC were enrolled. An additional four normal liver (NL) samples were used as controls. SCCA1 expression in liver tissue was measured by immunochemistry. Another 28 HCC specimens and paired non-tumor tissues were used for SCCA1 detection by Western blot. The prognostic value of SCCA1 expression in HCC was evaluated by the Cox proportional hazards regression model analysis. Results: Western blot analysis showed SCCA1 positive rate in HCC was higher than the matched adjacent noncancerous tissues (p<0.001). Immunohistochemistry revealed thatSCCA1-positive rate increased gradually from NL, CHB, PNT to DN and HCC (p<0.05). Clinicopathological analysis showed that SCCA1 expression was positively associated with tumor differentiation (p=0.043) and patients' Child-Pugh score (p=0.021). The SCCA1-poistive group showed better overall survival than the negative group (p=0.029). Importantly, SCCA1 expression was an independent prognostic factor for the overall survival of HCC patients (hazard ratio=3.757, p<0.001). Conclusion: SCCA1 expression pattern may relate to the progression of chronic liver diseases. Furthermore, our study supports a potential association of negative SCCA1 expression with poor outcome in HCC. © 2015 IMSS. Source

Li S.,Tianjin Medical University | Gao Y.,Institute for Hepatobiliary Disease | Yang B.,Institute for Hepatobiliary Disease | Liang Z.,Tianjin Medical University | And 7 more authors.
Neoplasma | Year: 2014

New tools for diagnostic of HCC remain to further investigate. We have evaluated the expression of SCCA1, 2 mRNA and their prognostic value in hepatocellular carcinoma (HCC).Reverse transcription polymerase chain reaction (RT-PCR) and direct sequencing were performed to evaluate the mRNA expression of SCCA1 and SCCA2 in 93 HCCs, and 93 paired adjacent non-cancerous tissues (PNT), 16 cirrhosis livers and 9 normal livers. The correlation of SCCA variants expression with the clinical parameters and the factors affecting survival were analyzed statistically. Total SCCA was detected in 33.3% of HCCs (31/93), in 9.68% of PNT (9/93) and 22.2% of normal livers (2/9). No expression was found in cirrhosis livers (0/16). The frequencies of total SCCA expression were significantly higher in HCCs than that in PNT and liver cirrhosis (p = 0.000, 0.006). From mRNA sequencing of HCCs, a new SCCA1 variant (presenting a T357A mutation) was identified in 16 specimens, while wild type SCCA1 was identified in 11 specimens and SCCA2 in 27 specimens. Clinicopathological analysis showed that the frequency of SCCA1 was significantly higher in poorly differentiated HCC, compared with moderately and well differentiated tumors (p = 0.021). T357A variant has a significantly higher frequency in nonencapsulated tumors than wild type SCCA1 (p = 0.034).The SCCA1, 2 mRNA is effective for detecting HCC and could be potentially applied in HCC diagnosis. © 2014 Cancer Research Institute Slovak Acad. of Sciences. All rights reserved. Source

Discover hidden collaborations